Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Ortiz-Espinosa

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancer Research|August 15, 2023
Bursting Tumor Bubbles to Improve CAR T-cell TherapySergio Ortiz-Espinosa, Shivani Srivastava
Seminars in Cell & Developmental Biology|November 21, 2017
Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatmentDaniel Ajona, Sergio Ortiz-Espinosa, Ruben Pio
Frontiers in Immunology|April 20, 2019
Complement in Metastasis: A Comp in the CampDaniel Ajona, Sergio Ortiz-Espinosa, Ruben Pio, et al.
Frontiers in Immunology|April 30, 2019
Complementing the Cancer-Immunity CycleRuben Pio, Daniel Ajona, Sergio Ortiz-Espinosa, et al.
Plos One|June 28, 2023
Gene knock-outs in human CD34+ hematopoietic stem and progenitor cells and in the human immune system of miceDaniel A Kuppers, Jonathan Linton, Sergio Ortiz Espinosa, et al.
Cancer Discovery|March 15, 2017
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and MetastasisDaniel Ajona, Sergio Ortiz-Espinosa, Haritz Moreno, et al.
American Journal of Respiratory and Critical Care Medicine|January 13, 2018
Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated EffectsDaniel Ajona, Carolina Zandueta, Leticia Corrales, et al.
Bioengineering & Translational Medicine|September 30, 2022
Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in bloodAlejandro Rodríguez-Pena, Estibaliz Armendariz, Alvaro Oyarbide, et al.
Journal for Immunotherapy of Cancer|March 4, 2021
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferationEsther Redin, Irati Garmendia, Teresa Lozano, et al.
Journal of Hepatology|April 22, 2021
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targetedAdrián Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancer Research|August 15, 2023
Bursting Tumor Bubbles to Improve CAR T-cell TherapySergio Ortiz-Espinosa, Shivani Srivastava
Seminars in Cell & Developmental Biology|November 21, 2017
Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatmentDaniel Ajona, Sergio Ortiz-Espinosa, Ruben Pio
Frontiers in Immunology|April 20, 2019
Complement in Metastasis: A Comp in the CampDaniel Ajona, Sergio Ortiz-Espinosa, Ruben Pio, et al.
Frontiers in Immunology|April 30, 2019
Complementing the Cancer-Immunity CycleRuben Pio, Daniel Ajona, Sergio Ortiz-Espinosa, et al.
Plos One|June 28, 2023
Gene knock-outs in human CD34+ hematopoietic stem and progenitor cells and in the human immune system of miceDaniel A Kuppers, Jonathan Linton, Sergio Ortiz Espinosa, et al.
Cancer Discovery|March 15, 2017
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and MetastasisDaniel Ajona, Sergio Ortiz-Espinosa, Haritz Moreno, et al.
American Journal of Respiratory and Critical Care Medicine|January 13, 2018
Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated EffectsDaniel Ajona, Carolina Zandueta, Leticia Corrales, et al.
Bioengineering & Translational Medicine|September 30, 2022
Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in bloodAlejandro Rodríguez-Pena, Estibaliz Armendariz, Alvaro Oyarbide, et al.
Journal for Immunotherapy of Cancer|March 4, 2021
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferationEsther Redin, Irati Garmendia, Teresa Lozano, et al.
Journal of Hepatology|April 22, 2021
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targetedAdrián Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, et al.
Pageof 2